| # | Title | Journal | Year | Citations |
|---|
| 1 | Stability of SARS-CoV-2 in different environmental conditions | Lancet Microbe, The | 2020 | 1,479 |
| 2 | SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis | Lancet Microbe, The | 2021 | 1,111 |
| 3 | Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study | Lancet Microbe, The | 2020 | 683 |
| 4 | Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study | Lancet Microbe, The | 2020 | 441 |
| 5 | Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis | Lancet Microbe, The | 2022 | 436 |
| 6 | SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study | Lancet Microbe, The | 2020 | 434 |
| 7 | Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study | Lancet Microbe, The | 2020 | 422 |
| 8 | SARS-CoV-2 spike E484K mutation reduces antibody neutralisation | Lancet Microbe, The | 2021 | 344 |
| 9 | Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study | Lancet Microbe, The | 2021 | 322 |
| 10 | Co-infections: potentially lethal and unexplored in COVID-19 | Lancet Microbe, The | 2020 | 279 |
| 11 | WHO's Global Tuberculosis Report 2022 | Lancet Microbe, The | 2023 | 277 |
| 12 | Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study | Lancet Microbe, The | 2021 | 274 |
| 13 | The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries | Lancet Microbe, The | 2022 | 255 |
| 14 | An integrated national scale SARS-CoV-2 genomic surveillance network | Lancet Microbe, The | 2020 | 232 |
| 15 | Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study | Lancet Microbe, The | 2021 | 216 |
| 16 | Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection study | Lancet Microbe, The | 2020 | 160 |
| 17 | Diagnosing COVID-19-associated pulmonary aspergillosis | Lancet Microbe, The | 2020 | 158 |
| 18 | COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room | Lancet Microbe, The | 2021 | 152 |
| 19 | The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study | Lancet Microbe, The | 2021 | 147 |
| 20 | Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study | Lancet Microbe, The | 2020 | 133 |
| 21 | T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study | Lancet Microbe, The | 2022 | 131 |
| 22 | Genomic surveillance to combat COVID-19: challenges and opportunities | Lancet Microbe, The | 2021 | 122 |
| 23 | The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis | Lancet Microbe, The | 2022 | 114 |
| 24 | WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study | Lancet Microbe, The | 2021 | 112 |
| 25 | Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19 | Lancet Microbe, The | 2021 | 112 |
| 26 | Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study | Lancet Microbe, The | 2021 | 109 |
| 27 | WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community | Lancet Microbe, The | 2022 | 108 |
| 28 | SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study | Lancet Microbe, The | 2022 | 107 |
| 29 | Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study | Lancet Microbe, The | 2020 | 92 |
| 30 | Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study | Lancet Microbe, The | 2021 | 92 |
| 31 | Global human monkeypox outbreak: atypical presentation demanding urgent public health action | Lancet Microbe, The | 2022 | 88 |
| 32 | Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study | Lancet Microbe, The | 2020 | 86 |
| 33 | Dynamics of mcr-1 prevalence and mcr-1-positive Escherichia coli after the cessation of colistin use as a feed additive for animals in China: a prospective cross-sectional and whole genome sequencing-based molecular epidemiological study | Lancet Microbe, The | 2020 | 85 |
| 34 | The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly | Lancet Microbe, The | 2022 | 80 |
| 35 | Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study | Lancet Microbe, The | 2021 | 78 |
| 36 | Definition of a genetic relatedness cutoff to exclude recent transmission of meticillin-resistant Staphylococcus aureus: a genomic epidemiology analysis | Lancet Microbe, The | 2020 | 75 |
| 37 | Systematic SARS-CoV-2 screening in cerebrospinal fluid during the COVID-19 pandemic | Lancet Microbe, The | 2020 | 74 |
| 38 | Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study | Lancet Microbe, The | 2020 | 74 |
| 39 | Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis | Lancet Microbe, The | 2020 | 71 |
| 40 | Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics | Lancet Microbe, The | 2021 | 71 |
| 41 | Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study | Lancet Microbe, The | 2021 | 67 |
| 42 | Stability of SARS-CoV-2 in different environmental conditions – Authors' reply | Lancet Microbe, The | 2020 | 66 |
| 43 | COVID-19 testing in Africa: lessons learnt | Lancet Microbe, The | 2020 | 65 |
| 44 | Low rate of bacterial co-infection in patients with COVID-19 | Lancet Microbe, The | 2020 | 64 |
| 45 | COVID-19 cytokine storm syndrome: a threshold concept | Lancet Microbe, The | 2021 | 64 |
| 46 | Invasive mould disease in fatal COVID-19: a systematic review of autopsies | Lancet Microbe, The | 2021 | 62 |
| 47 | SARS-CoV-2 spike and its adaptable furin cleavage site | Lancet Microbe, The | 2021 | 62 |
| 48 | Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis | Lancet Microbe, The | 2021 | 60 |
| 49 | COVID-19 vaccines: the pandemic will not end overnight | Lancet Microbe, The | 2021 | 56 |
| 50 | WHO international standard for SARS-CoV-2 antibodies to determine markers of protection | Lancet Microbe, The | 2022 | 56 |
